PEGS Boston 2026

Advance your Biologics Discovery with Cutting-Edge Bruker Technology at PEGS Boston 2026!

Register today to explore Bruker’s unparalleled portfolio of analytical technologies for Biologics development. Our cutting-edge optofluidic and biophysical platforms unlock new possibilities in your discovery workflows. Capabilities range from single B cell and T cell screening to high-throughput epitope binning to kinetic measurements directly on cells.

Accelerate your research with the innovative tools trusted by leading scientists and pharmaceutical innovators around the globe. Find out more below.

• Meet us at Booth 317+319: We're looking forward to meeting you in front of our biosensors and Beacon^® solutions that will be on display at our booths. Take the chance to discuss with our experts how our solutions can help you in current and future projects.

• Podium presentations: Attend our podium presentations to discover the latest on Bruker’s Biosensors and Beacon antibody screening solutions.

May 12, 10:05 – 10:35 am  EDT

Track: Antibodies for Cancer Therapy

From high-throughput screening to kinetics directly on cells: streamlining antibody discovery with biophysical insights

As antibody formats grow more complex, precise biophysical characterization becomes essential. We present a workflow combining high-throughput SPR for epitope binning and interaction screening, switchSENSE^® for affinity vs. avidity and ternary complex detection, and single-cell Interaction Cytometry for real-time kinetics on living cells in native context. Together, these tools support informed antibody design and selection.

May 13, 3:10- 3:40 pm EDT

Track: Advancing Multispecific Antibodies and Combination Therapy to the Clinic

Function-First Single-Cell Discovery and Characterization of Bispecific T Cell Engagers 

Traditional multispecifics discovery focuses on first identifying monoclonal antibody binders, while pushing functional characterization and engineering into later, more expensive screening.

As therapeutic modalities become more complex and engineering becomes another constraint, the Beacon^® optofluidic platform enable researchers to characterize antibodies and bispecifics for function first and expand beyond bulk screening.

We will highlight a recent T cell engager screening case study against functional cytotoxicity and multiple cytokine secretion with single-cell granularity. 

Discover the scientific posters showcasing application examples of our technologies: 

2BIND
Binding kinetics measured on cells – pain or gain?

BRUKER BIOSENSORS
Integrated biophysical analysis of Fc–FcR binding, affinity, and avidity in antibody therapeutics

BRUKER CELLULAR ANALYSIS
Function-first single-cell discovery and characterization of bispecific T cell engagers

ROUKENBIO
Target density matters - binding kinetics of antibody-based therapeutics are highly influenced by target expression levels

As you are certainly aware, special compliance regulations apply to public officials* and healthcare professionals** with regard to the event we are planning. If you accept our invitation, we will therefore assume that you will observe the compliance regulations that apply to you and that you have the necessary employer approval.

*Government Official means according the Bruker policies any of the following: any officer, employee or representative of a government (national, regional or local) entity, or any public agency, public authority, department or instrumentality thereof, regardless of their rank or title (e.g. a regulatory official or government inspector); any person working for or advising a government-owned or government-controlled enterprise (e.g. a professor at a government-owned university, or a purchaser at a government-owned hospital); any person working for or advising a national or international non-governmental organization (e.g. an employee of the Red Cross or The World Bank); any person performing a public function or providing a public service, even if that person works for a non-governmental institution (e.g. private security personnel working in public functions); any person hired to review or accept bids for a government agency; any person with the responsibility to allocate or expend government funds; any person in a public law function, civil servant, judge or military personnel; any person acting for a political party, including party officials, candidates or individuals holding a position in a political party office; members of royal families; or immediate family members of any of the persons listed above. An immediate family member is a grandparent, parent, spouse, significant other, child, or sibling.

**A Healthcare Professional (HCP) is in accordance with the Bruker policies any physician, dentist, nurse, pharmacist or other individual who may prescribe, administer, purchase, dispense, recommend, or supply medical products or treatments or pharmaceutical products. In many cases, Bruker interacts with HCPs who work for state-owned hospitals (e.g. as medical scientists). These individuals will be classified as both HCPs and Government Officials.